European Primary Care Cardiovascular Society

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

Widespread atherosclerosis in Swedish population

3' education - Dec. 3, 2020 - Prof. Göran Bergström, MD, PhD

Potentially no contradiction between omega-3 fatty acids trials

3' education - Dec. 3, 2020 - Prof. Deepak Bhatt, MD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Omega-3 carboxylic acid has no effect on MACE in high risk patients

3' education - Dec. 3, 2020 - Prof. Michael Lincoff, MD

A polypill with or without aspirin to reduce global CVD burden

3' education - Dec. 3, 2020 - Prof. Salim Yusuf, MD

Reduced HF hospitalization in iron deficient patient after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

An update on COVID-19 at the AHA Scientific Sessions

10' education - Dec. 3, 2020 - Anthony Fauci, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

Primary outcome reduced by anti-inflammatory drug in chronic coronary disease

3' education - Sep. 30, 2020 - Mark Nidorf, MD

Temporarily suspending or continuing ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 30, 2020 - Prof. Renato D. Lopes, MD, PhD

Consideration of BP lowering irrespective of prior CVD or baseline SBP

3' education - Sep. 30, 2020 - Kazem Rahimi, MD

Changes in the 2020 AF guidelines

3' education - Sep. 30, 2020 - Prof. Isabelle van Gelder, MD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD

Proportion of unrecognized MI greater in women

5' education - Aug. 19, 2020 - Yldau van der Ende, MD, PhD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD
Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.

AHA 2020 Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.

Widespread atherosclerosis in Swedish population

3' education - Dec. 3, 2020 - Prof. Göran Bergström, MD, PhD
Prevalence of silent CAD and identification of those with high risk of CAD were examined in the Swedish SCAPIS cohort.

AHA 2020 Prevalence of silent CAD and identification of those with high risk of CAD were examined in the Swedish SCAPIS cohort.

Potentially no contradiction between omega-3 fatty acids trials

3' education - Dec. 3, 2020 - Prof. Deepak Bhatt, MD
Prof. Bhatt responds to the presentation of the STRENGTH, in which the results were compared to those of REDUCE-IT. He addressed the differences in composition of the study drugs in the two trials.

AHA 2020 Prof. Bhatt responds to the presentation of the STRENGTH trial, in which the results were compared to those of REDUCE-IT. He addresses the differences in composition of the study drugs in the two trials.

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD
Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

Omega-3 carboxylic acid has no effect on MACE in high risk patients

3' education - Dec. 3, 2020 - Prof. Michael Lincoff, MD
The STRENGTH trial, evaluating the combination of EPA and DHA, was stopped due to futility. Prof. Lincoff speculates why these results are different than those of the REDUCE-IT trial.

AHA 2020 The STRENGTH trial, evaluating the combination of EPA and DHA, was stopped due to futility. Prof. Lincoff speculates why these results differ from those of the REDUCE-IT trial.

A polypill with or without aspirin to reduce global CVD burden

3' education - Dec. 3, 2020 - Prof. Salim Yusuf, MD
A polypill may be an effective, safe and simple approach to reach lots of people to reduce the global burden of serious CVD. Prof. Salim Yusuf discusses the TIPS trial.

AHA 2020 A polypill may be an effective, safe and simple approach to reach lots of people to reduce the global burden of serious CVD. Prof. Salim Yusuf discusses the TIPS trial.

Reduced HF hospitalization in iron deficient patient after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

An update on COVID-19 at the AHA Scientific Sessions

10' education - Dec. 3, 2020 - Anthony Fauci, MD
Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

CV outcomes and all-cause death not reduced with omega-3 FA in elderly MI patients

News - Nov. 26, 2020

AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.

Kidney and CV risk reduction with nonsteroidal MRA in T2DM patients with CKD

News - Nov. 26, 2020

AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

Reduction CV events with polypill and aspirin in primary prevention setting

News - Nov. 26, 2020

AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.